Comparison

Semaglutid vs. VK2735

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Semaglutid

Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Semaglutid	VK2735
Switzerland	Prescription	—
Germany	Prescription	Unapproved
United States	Prescription	Unapproved

Full entries

Frequently asked questions

What is the difference between Semaglutid and VK2735?: Semaglutid is classified as "Metabolic", while VK2735 is classified as "Metabolic". Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Semaglutid or VK2735?: The highest available evidence level is "Human RCT" for Semaglutid and "Human RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Semaglutid and VK2735 in Germany and the United States?: Germany: Semaglutid — Prescription, VK2735 — Unapproved. United States: Semaglutid — Prescription, VK2735 — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Semaglutid

VK2735

Switzerland

Prescription

—

Germany

Prescription

Unapproved

United States

Prescription

Unapproved

Frequently asked questions

What is the difference between Semaglutid and VK2735?

Semaglutid is classified as "Metabolic", while VK2735 is classified as "Metabolic". Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Semaglutid or VK2735?

The highest available evidence level is "Human RCT" for Semaglutid and "Human RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Semaglutid and VK2735 in Germany and the United States?

Germany: Semaglutid — Prescription, VK2735 — Unapproved. United States: Semaglutid — Prescription, VK2735 — Unapproved. These are factual summaries with source and review date on the individual pages.